Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing

被引：9

作者：

Agiannitopoulos, Konstantinos ^{[1
]}

Potska, Kevisa ^{[1
]}

Katseli, Anastasia ^{[1
]}

Ntogka, Christina ^{[1
]}

Tsaousis, Georgios N. ^{[1
]}

Pepe, Georgia ^{[1
]}

Bouzarelou, Dimitra ^{[1
]}

Tsoulos, Nikolaos ^{[1
]}

Papathanasiou, Athanasios ^{[1
]}

Ziogas, Dimitrios ^{[2
]}

Venizelos, Vassileios ^{[3
]}

Markopoulos, Christos ^{[4
]}

Iosifidou, Rodoniki ^{[5
]}

Karageorgopoulou, Sofia ^{[6
]}

Giassas, Stylianos ^{[6
]}

Natsiopoulos, Ioannis ^{[7
]}

Papazisis, Konstantinos ^{[8
]}

Vasilaki-Antonatou, Maria ^{[9
]}

Psyrri, Amanta ^{[10
]}

Koumarianou, Anna ^{[10
]}

Matthaios, Dimitrios ^{[11
]}

Zairi, Eleni ^{[12
]}

Blidaru, Alexandru ^{[13
]}

Banu, Eugeniu ^{[14
]}

Jinga, Dan Corneliu ^{[15
]}

Lacin, Sahin ^{[16
]}

Ozdogan, Mustafa ^{[17
]}

Papadopoulou, Eirini ^{[1
]}

Nasioulas, George ^{[1
]}

机构：

[1] Genekor Med SA, Athens 15344, Greece

[2] Gen Hosp Athens LAIKO, Athens 11527, Greece

[3] Metropolitan Hosp, Athens 18547, Greece

[4] Athens Med Ctr, Athens 15125, Greece

[5] Theagenio Anticanc Hosp, Thessaloniki 54639, Greece

[6] IASO, Gen Matern & Gynecol Clin, Athens 15123, Greece

[7] Interbalkan Med Ctr Thessaloniki, Thessaloniki 55535, Greece

[8] Euromed Gen Clin, Thessaloniki 54636, Greece

[9] Metropolitan Gen Hosp, Athens 15562, Greece

[10] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sect Med Oncol, Athens 12462, Greece

[11] Gen Hosp Rhodes, Rhodes 85133, Greece

[12] St Lukes Hosp, Thessaloniki 55236, Greece

[13] Alexandru Trestioreanu Bucharest Oncol Inst, Bucharest 022328, Romania

[14] St Constantin Hosp, Brasov 500299, Romania

[15] Neolife Med Ctr, Bucharest 013812, Romania

[16] Koc Univ, Fac Med, Dept Med Oncol, TR-34010 Istanbul, Turkiye

[17] Mem Antalya Hosp, Div Med Oncol, TR-07025 Antalya, Turkiye

来源：

CANCERS | 2023年 / 15卷 / 21期

关键词：

cascade family testing; hereditary breast cancer; next-generation sequencing; HEREDITARY BREAST;

D O I：

10.3390/cancers15215218

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary The aim of this study was to explore the utility of cascade family testing (CFT) in families of breast cancer patients who carry specific genetic variations. We conducted genetic analysis in a group of breast cancer patients and identified genetic variations in over 20% of them; thus, CFT was recommended to their first-degree relatives. Among those tested, the majority were asymptomatic females and mainly offspring, siblings, or parents of the patients. The study showed that CFT was most commonly performed in families with high-risk genetic findings, and we concluded that CFT could be a valuable approach for preventing hereditary cancers by identifying at-risk family members. We also emphasized the need for improved genetic counseling and communication to ensure effective implementation.Abstract Background: Hereditary cancer predisposition syndromes are responsible for approximately 5-10% of all diagnosed cancer cases. In order to identify individuals at risk in a cost-efficient manner, family members of individuals carrying pathogenic alterations are tested only for the specific variant that was identified in their carrier relative. The purpose of this study was to investigate the clinical use and implementation of cascade family testing (CFT) in families of breast cancer patients with pathogenic/likely pathogenic variants (PVs/LPVs) in cancer-related predisposition genes. Methods: Germline sequencing was carried out with NGS technology using a 52-gene panel, and cascade testing was performed by Sanger sequencing or MLPA. Results: In a cohort of 1785 breast cancer patients (families), 20.3% were found to have PVs/LPVs. Specifically, 52.2%, 25.1%, and 22.7% of patients had positive findings in high-, intermediate-, and low-penetrance breast cancer susceptibility genes, respectively. Although CFT was recommended to all families, only 117 families (32.3%) agreed to proceed with genetic testing. Among the first-degree relatives who underwent CFT, 70.3% were female, and 108 of 121 (89.3%) were cancer free. Additionally, 42.7%, 36.7%, and 20.6% were offspring, siblings, and parents of the subject, respectively. Our data suggest that CFT was mostly undertaken (104/117, 88.8%) in families with positive findings in high-risk genes. Conclusions: Cascade family testing can be a powerful tool for primary cancer prevention by identifying at-risk family members. It is of utmost importance to implement genetic counseling approaches leading to increased awareness and communication of genetic testing results.

引用

页数：10

共 24 条

[1] Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing [J].

Agiannitopoulos, Konstantinos ;

Pepe, Georgia ;

Tsaousis, Georgios N. ;

Potska, Kevisa ;

Bouzarelou, Dimitra ;

Katseli, Anastasia ;

Ntogka, Christina ;

Meintani, Angeliki ;

Tsoulos, Nikolaos ;

Giassas, Stylianos ;

Venizelos, Vassileios ;

Markopoulos, Christos ;

Iosifidou, Rodoniki ;

Karageorgopoulou, Sofia ;

Christodoulou, Christos ;

Natsiopoulos, Ioannis ;

Papazisis, Konstantinos ;

Vasilaki-Antonatou, Maria ;

Kabletsas, Eleftherios ;

Psyrri, Amanta ;

Ziogas, Dimitrios ;

Lalla, Efthalia ;

Koumarianou, Anna ;

Anastasakou, Kornilia ;

Papadimitriou, Christos ;

Ozmen, Vahit ;

Tansan, Sualp ;

Kaban, Kerim ;

Ozatli, Tahsin ;

Eniu, Dan Tudor ;

Chiorean, Angelica ;

Blidaru, Alexandru ;

Rinsma, Marrit ;

Papadopoulou, Eirini ;

Nasioulas, George .

CANCER GENOMICS & PROTEOMICS, 2023, 20 (05) :448-455

[2] Assessing relatives' readiness for hereditary cancer cascade genetic testing [J].

Bednar, Erica M. ;

Sun, Charlotte C. ;

McCurdy, Sheryl ;

Vernon, Sally W. .

GENETICS IN MEDICINE, 2020, 22 (04) :719-726

[3] Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative [J].

Caswell-Jin, Jennifer L. ;

Zimmer, Anjali D. ;

Stedden, Will ;

Kingham, Kerry E. ;

Zhou, Alicia Y. ;

Kurian, Allison W. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (01) :95-98

[4] NCCN: Continuing Education [J].

Daly, Mary B. ;

Pilarski, Robert ;

Yurgelun, Matthew B. ;

Berry, Michael P. ;

Buys, Saundra S. ;

Dickson, Patricia ;

Domchek, Susan M. ;

Elkhanany, Ahmed ;

Friedman, Susan ;

Garber, Judy E. ;

Goggins, Michael ;

Hutton, Mollie L. ;

Khan, Seema ;

Klein, Catherine ;

Kohlmann, Wendy ;

Kurian, Allison W. ;

Laronga, Christine ;

Litton, Jennifer K. ;

Mak, Julie S. ;

Menendez, Carolyn S. ;

Merajver, Sofia D. ;

Norquist, Barbara S. ;

Offit, Kenneth ;

Pal, Tuya ;

Pederson, Holly J. ;

Reiser, Gwen ;

Shannon, Kristen Mahoney ;

Visvanathan, Kala ;

Weitzel, Jeffrey N. ;

Wick, Myra J. ;

Wisinski, Kari B. ;

Dwyer, Mary A. ;

Darlow, Susan D. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (04) :380-391

[5] Beyond BRCA: New hereditary breast cancer susceptibility genes [J].

Economopoulou, P. ;

Dimitriadis, G. ;

Psyrri, A. .

CANCER TREATMENT REVIEWS, 2015, 41 (01) :1-8

[6] Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives [J].

Evans, D. G. R. ;

Binchy, A. ;

Shenton, A. ;

Hopwood, P. ;

Craufurd, D. .

CLINICAL GENETICS, 2009, 75 (02) :124-132

[7] Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review [J].

Fournier, Danielle M. ;

Bazzell, Angela F. ;

Dains, Joyce E. .

ONCOLOGY NURSING FORUM, 2018, 45 (01) :96-105

[8] Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis [J].

Frey, Melissa K. ;

Ahsan, Muhammad Danyal ;

Bergeron, Hannah ;

Lin, Jenny ;

Li, Xuan ;

Fowlkes, Rana K. ;

Narayan, Priyanka ;

Nitecki, Roni ;

Rauh-Hain, Jose Alejandro ;

Moss, Haley A. ;

Baltich Nelson, Becky ;

Thomas, Charlene ;

Christos, Paul J. ;

Hamilton, Jada G. ;

Chapman-Davis, Eloise ;

Cantillo, Evelyn ;

Holcomb, Kevin ;

Kurian, Allison W. ;

Lipkin, Steven ;

Offit, Kenneth ;

Sharaf, Ravi N. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) :4129-+

[9] What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing [J].

Frey, Melissa K. ;

Ahsan, Muhammad Danyal ;

Badiner, Nora ;

Lin, Jenny ;

Narayan, Priyanka ;

Nitecki, Roni ;

Rauh-Hain, Jose Alejandro ;

Moss, Haley ;

Fowlkes, Rana Khan ;

Thomas, Charlene ;

Bergeron, Hannah ;

Christos, Paul ;

Levi, Sarah R. ;

Blank, Stephanie, V ;

Holcomb, Kevin ;

Cantillo, Evelyn ;

Sharaf, Ravi N. ;

Lipkin, Steven ;

Offit, Kenneth ;

Chapman-Davis, Eloise .

CANCER, 2022, 128 (24) :4241-4250

[10] Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling [J].

Garcia, Christine ;

Sullivan, Mackenzie W. ;

Lothamer, Heather ;

Harrison, Kara M. ;

Chatfield, Lindsay ;

Thomas, Martha H. ;

Modesitt, Susan C. .

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2020, 46 (09) :1835-1841

← 1 2 3 →